Skip to main content
HOUSE 4005118th CongressReferred to the Subcommittee on Health.

Naloxone Affordability Act of 2023

Last Action
6/16/2023

Actions

  • 2023-06-16Referred to the Subcommittee on Health.
  • 2023-06-12Referred to the House Committee on Energy and Commerce.
  • 2023-06-12Introduced in House
  • 2023-06-12Introduced in House

CRS Summary

As of 2023-06-12 (00)

Naloxone Affordability Act of 2023

This bill requires the Government Accountability Office to study access to and affordability of naloxone (a medication that temporarily reverses opioid overdoses). The study must address matters related to out-of-pocket costs that consumers pay for naloxone and coverage for naloxone as an over-the-counter drug through Medicare, Medicaid, and private health insurance.

Historically, naloxone required a prescription and so was typically covered by health insurance. However, the Food and Drug Administration approved Narcan (a naloxone hydrochloride nasal spray) for use without a prescription on March 29, 2023, and health insurance does not generally cover over-the-counter medications.


Cosponsors (2)

  • Lisa Blunt Rochester (D-DE)
  • Angie Craig (D-MN)

Subjects

  • Congressional oversight
  • Drug therapy
  • Drug, alcohol, tobacco use
  • Government studies and investigations
  • Health care costs and insurance
  • Health care coverage and access
  • Medicaid
  • Medicare
  • Prescription drugs
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.